Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
April 11, 20213:40 PM PDTLast Updated 4 months ago
Healthcare & Pharmaceuticals
Brazil sees 1,803 COVID-19 deaths; Chinese vaccine found 50.7% effective against variant
Reuters

2 minute read
A patient who died from the coronavirus disease (COVID-19) is transported to the morgue at a field hospital set up at Dell'Antonia sports gym in Santo Andre, on the outskirts of Sao Paulo, Brazil April 7, 2021. REUTERS/Amanda Perobelli
SAO PAULO, April 11 (Reuters) - Brazil on Sunday recorded 1,803 new COVID-19 deaths, as a large study found that a Chinese vaccine that has become the linchpin in the country's vaccination campaign is 50.7% effective against the infectious new homegrown variant known as P1.
Brazil, which has in recent weeks become the global epicenter of the coronavirus pandemic, saw over 37,000 new cases, the Health Ministry said on Sunday. With over 353,000 deaths, Latin America's biggest country has the second highest coronavirus death toll in the world, after the United States.
The outbreak has recently reached its most severe phase due to a lack of federal restrictions, a patchy vaccine rollout and the P1 variant.
Sao Paulo's Butantan biomedical institute, which tested and is now producing the CoronaVac vaccine developed by China's Sinovac Biotech Ltd (SVA.O), said on Sunday a study it conducted found the shot had an efficacy rate of 50.7% against the P1 variant, and a less widespread strain known as P2.
Brazilian President Jair Bolsonaro, a China hawk and vaccine skeptic who has come under fire for his handling of the outbreak, initially said his government would not buy the Sinovac shot, but later made a U-turn as his government struggled to secure supplies. Since then, the Chinese shot has become the most widely administered one in the country.
Butantan said that if the second dose is delayed by more than two weeks, the efficacy rises to 62.3%. The vaccine has an efficacy of between 83.7% and 100% at preventing those infected from requiring medical assistance, it said.
The study, which it said had been sent to the medical journal The Lancet for publication, tested 12,400 volunteers across Brazil.
Reporting by Alexandre Caverni; Editing by Peter Cooney
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page
Read Next
Asia Pacific
Sydney to get more vaccines as COVID cases mount
11:15 PM PDT
India
India reports 39,097 new covid-19 cases in last 24 hours - govt
9:39 PM PDT
United States
U.S. appeals court lifts CDC cruise ship restrictions in win for Florida
8:47 PM PDT
United States
CDC says mask rules will apply to Florida cruise ships not following sail order
7:43 PM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 10:46 AM PDT
Vaccinated people make up 75% of recent COVID-19 cases in Singapore, but few fall ill
Vaccinated individuals accounted for three-quarters of Singapore's COVID-19 infections in the last four weeks, but they were not falling seriously ill, government data showed, as a rapid ramp-up in inoculations leaves fewer people unvaccinated.
Healthcare & Pharmaceuticals
White House says new Pfizer vaccine order could help if booster shot needed
11:12 AM PDT
Healthcare & Pharmaceuticals
United States buys 200 mln more doses of Pfizer/BioNTech COVID-19 vaccine
10:14 AM PDT
Healthcare & Pharmaceuticals
Mexico City's third wave of pandemic drives up hospital occupancy
12:55 PM PDT
Healthcare & Pharmaceuticals
China's Sinovac evaluates vaccine plant in Chile
1:00 PM PDT
Latest
Home
Media
Videos
Pictures
Graphics
Browse
World
Business
Legal
Markets
Breakingviews
Technology
Investigations
Lifestyle
About Reuters
About Reuters
Careers
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Newsletters
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Westlaw
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
Onesource
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
Checkpoint
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Eikon
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
World-Check
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Cookies
Terms of Use
Privacy
Corrections
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved